This partnership
is personal

The future of individualized answers in cancer genomics

Pathology and Clinical Cancer Research

Cutting-edge clinical cancer research solutions from Illumina deliver the accurate information your lab needs to improve the quality of your reporting and optimize care. Rapidly analyze expert-defined genes and mutation hotspots to find actionable variants in any type of cancer, including solid tumors and hematological malignancies.

Our workflow solutions for translational cancer research include both fixed and customizable cancer panels and a comprehensive range of systems that can be scaled to meet your needs. Our multi-analyte approach enables you to get thorough information efficiently and cost-effectively, even from small specimens. In addition, these integrated solutions include data analysis and reporting capabilities to help you communicate significant findings effectively.

Achieve Comprehensive NTRK Fusion Screening
Achieve Comprehensive NTRK Fusion Screening

In this webinar, learn about a hybrid-capture next-generation sequencing (NGS) assay that queries RNA and is able to detect all NTRK fusions, agnostic of fusion partners.

View Webinar

Jaclyn Hechtman, MD, Associate Attending Pathologist at Memorial Sloan Kettering Cancer Center, discusses the relevance of RET alterations in non-small cell lung cancer and the pros and cons of different technical approaches to identify RET fusions and single-nucleotide variants.

View Webinar
Lung Cancer

Featured Clinical Cancer Research Articles

Accurate Identification of Cancer Biomarkers Paves the Way for Personalized Medicine
Accurate Identification of Cancer Biomarkers Paves the Way for Personalized Medicine

An NGS panel enables translational cancer researchers to seek answers to multiple questions in one assay.

Read Interview
The Changing Landscape of NGS Implementation in Molecular Diagnostic Laboratories
The Changing Landscape of NGS Implementation in Molecular Diagnostic Laboratories

Key opinion leaders discuss the ongoing challenges and potential of NGS in oncology testing.

Read Interview
New Liquid Biopsy and High-Throughput Assays Join TruSight Oncology Portfolio
TruSight Oncology Family Grows with Liquid Biopsy and High-Throughput Assays

The latest additions to the Illumina portfolio of comprehensive cancer profiling assays provide labs with the flexibility to run tissue or blood plasma samples on a single high-throughput platform.

Read Article

Dr Rossi highlights the value of NGS for oncology, including the cost-effective analysis of multiple genes in a single test.

View Video
Advancing Clinical Cancer Research with NGS
icon DNA

NGS Workflow Finder

Take the guesswork out of your next workflow. The NGS Workflow Finder provides personalized solution recommendations and resources so you can sequence with confidence.

Find your NGS workflow today
Accurate Gene Fusion Detection in Sarcomas
Accurate Gene Fusion Detection in Sarcomas

With NGS, you can easily survey hundreds of genes to detect known and novel fusion partners and characterize sarcoma subtypes.

Access PDF
NGS in pathology labs | Illumina Webinar
NGS in Pathology Labs

Dr Rachel Butler discusses why their lab adopted NGS and explains its advantages in molecular pathology for profiling solid tumor samples.

View Video
Interested in receiving newsletters, case studies, and information on cancer genomics?
Sign Up
Introduction to NGS for Pathologists
Introduction to NGS for Pathologists

Visit our Medical Genetics website to download an introduction to NGS technology and applications for molecular pathologists.

Learn More
Next-Generation Sequencing of FFPE Tumor Specimens
NGS for FFPE Tumor Specimens

Dr Rossi explains the value of molecular testing, and helps newcomers to NGS explore targeted sequencing applications.

View Video
Pathology with Next-Generation Sequencing
Advancing Pathology with NGS

Dr Jaime Platt provides insights into the potential of NGS integration into clinical research, with case examples of deep sequencing in tumor samples.

View Video
Reimbursement Environment for NGS
Reimbursement Environment for NGS

Charles Mathews of Boston Healthcare discusses the reimbursement environment for next-generation sequencing.

View Video
Multi-site Validation of Solid Tumor Panel
Multi-Site Validation of Solid Tumor Panel

A study across seven different labs in Europe demonstrates the robustness of the TruSight Tumor 15 panel.

Access PDF